Loading
ZNF217 (Zinc finger protein 217) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer and Osteosarcoma.
Binds to the promoters of target genes and functions as repressor. Promotes cell proliferation and antagonises cell death. Promotes phosphorylation of AKT1 at 'Ser-473'.
CIViC holds 4 clinical evidence items and 0 assertions across 2 variants, naming Triciribine. Open Targets scores its association with cancer at 0.53 (direct and indirect evidence; datatypes literature 0.97, genetic association 0.66).
In plain words · ZNF217 (Zinc finger protein 217) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer and Osteosarcoma.
ZNF217 (Zinc finger protein 217) is a protein that switches other genes on and off. The public catalogues list it as a drug target and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Breast cancer, Ovarian cancer and Osteosarcoma.
Binds to the promoters of target genes and functions as repressor. Promotes cell proliferation and antagonises cell death.
No product in this corpus aims at ZNF217 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA ZNF217: RNA low tissue specificity; high antibody staining in 13 normal tissues; highest cancer staining carcinoid (2 of 4 high). Distribution: 3 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Breast cancer (all types), Ovarian cancer, Sarcomas (soft tissue, bone, GIST)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas ZNF217 tissue; Open Targets ENSG00000171940 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Collins et al, Proc. Natl. Acad. Sci. U.S.A, 1998, "Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma". Source.
Sources: HGNC HGNC:13009 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O75362 (protein name, function text, keywords and locations (REST API)); CIViC gene ZNF217 (4 evidence items, 0 assertions, 2 variants; diseases: Breast Cancer, Ovarian Cancer, Osteosarcoma (GraphQL API, CC0)); Open Targets ENSG00000171940 (association with cancer (MONDO_0004992) 0.53; (GraphQL API, CC0))
Binds to the promoters of target genes and functions as repressor. Promotes cell proliferation and antagonises cell death. Promotes phosphorylation of AKT1 at 'Ser-473'. Location: Nucleus (UniProt). Locus 20q13.2 (HGNC).
RNA: low tissue specificity, detected in many normal tissues.
Medium: Adrenal gland, Appendix, Breast, Bronchus, Caudate, Cerebellum, Endometrium, Epididymis.
Medium only: breast cancer, head and neck cancer, lymphoma, pancreatic cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"ZNF217" OR ABSTRACT:"ZNF217" OR TITLE:"zinc finger protein 217" OR ABSTRACT:"zinc finger protein 217" OR TITLE:"Zinc finger protein 217" OR ABSTRACT:"Zinc finger protein 217" OR TITLE:"ZABC1" OR ABSTRACT:"ZABC1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ZNF217, not a curated reading list.
Shares Osteosarcoma, Ovarian cancer, Breast cancer (all types), Open Targets Platform.
Shares Osteosarcoma, Open Targets Platform.
Shares Osteosarcoma, Open Targets Platform.
Shares Osteosarcoma, CIViC, Ovarian cancer, Open Targets Platform.
Shares Osteosarcoma, CIViC.
Shares Osteosarcoma, Ovarian cancer.